Paper Details

  1. Home
  2. Paper Details

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.

Author: AlvaradoYesid, AndersonKristin, BorthakurGautam, BosePrithviraj, BurgerJan, CortesJorge, DellasalaSara, EstrovZeev, FerrajoliAlessandra, JabbourElias, JainNitin, KantarjianHagop M, NaqviKiran, PaulShilpa, PemmarajuNaveen, SkinnerJeffrey, TakahashiKoichi, ThompsonPhilip, YilmazMusa

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study reports the long-term follow-up results of dasatinib at 50 mg daily as frontline therapy for chronic-phase chronic myeloid leukemia (CML-CP). Dasatinib is a potent Bcr-Abl tyrosine kinase inhibitor with known side effects like pleural effusions and myelosuppression. The 50 mg dose showed promising long-term efficacy and better tolerability compared to the standard 100 mg dose.
Paper Details　
Original Abstract of the Article :
Dasatinib, a potent Bcr-Abl tyrosine kinase inhibitor, is approved for the treatment of chronic-phase chronic myeloid leukemia (CML-CP) in the frontline and salvage settings. Notable side effects include pleural effusions and myelosuppression. Dasatinib at 50 mg daily has previously been reported to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/31553487

データ提供：米国国立医学図書館（NLM）

Long-Term Follow-Up of Lower Dose Dasatinib for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is like a persistent desert storm, requiring ongoing treatment. This study investigates the long-term effectiveness and safety of a lower dose of dasatinib, a medication used to treat CML, as a first-line therapy.

Lower Dose Dasatinib Shows Promise

The study found that a lower dose of dasatinib (50 mg daily) was well-tolerated and effective in treating newly diagnosed chronic-phase CML. The results suggest that this lower dose may be an alternative option for patients with CML, potentially reducing the risk of side effects associated with higher doses.

A Potential Alternative for CML Treatment

This study provides valuable insights into the long-term benefits of using a lower dose of dasatinib for CML treatment. The findings suggest that this approach may offer a more tolerable alternative, potentially improving patient quality of life.

Dr. Camel's Conclusion

This research offers a glimmer of hope for individuals with CML, suggesting that a lower dose of dasatinib may be an effective and well-tolerated treatment option. This study emphasizes the importance of personalized medicine, considering individual patient needs and potential risks and benefits of different treatment approaches.
Date :
  1. Date Completed 2020-07-02
  2. Date Revised 2021-10-23
Further Info :

Pubmed ID

31553487

DOI: Digital Object Identifier

NIHMS1615545

Related Literature

Article Analysis
・Side Effects of dasatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.